STRO
Sutro Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.07
−2.29%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$1.66
- Revenue estimate
- $13.6M
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$2.33
- EPS estimate
- -$2.19
- Revenue actual
- $9.8M
- Revenue estimate
- $12.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -26.5%
- Revenue beats (12Q)
- 8
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $47
- PT range
- $34 – $60
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026